Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 10/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.33 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14499235 | 0.87 | LMNA (0.40) | S1PR1S1PR3LMNAALDH1A1CYP3A4 | |
| SCHEMBL2622477 | 0.85 | MEN1 (0.55) | S1PR1S1PR3LMNAMEN1USP2 | |
| SCHEMBL18269849 | 0.82 | MEN1 (0.60) | S1PR1S1PR3LMNAMEN1USP2 | |
| SCHEMBL2632240 | 0.79 | MEN1 (0.42) | S1PR1S1PR3LMNAMEN1USP2 | |
| SCHEMBL2622475 | 0.76 | S1PR1 (0.42) | S1PR1S1PR3SMN1; SMN2TNNC1SGPL1 | |
| SCHEMBL10792748 | 0.72 | KCNH2 (0.51) | LMNAMEN1USP2ALDH1A1CYP3A4 | |
| SCHEMBL14309248 | 0.69 | KCNH2 (0.53) | LMNAMEN1USP2ALDH1A1CYP3A4 | |
| SCHEMBL20118857 | 0.69 | MEN1 (0.43) | S1PR1S1PR3LMNAMEN1ALDH1A1 | |
| SCHEMBL16900467 | 0.68 | RAB9A (0.49) | LMNAALDH1A1CYP3A4MAPK1KMT2A | |
| SCHEMBL28228923 | 0.68 | RAB9A (0.49) | LMNAALDH1A1CYP3A4MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | S1PR1 980/4885S1PR3 1425/4885LMNA 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.